Vitamin D in children with cystic fibrosis

Arch Dis Child. 2012 Nov;97(11):982-4. doi: 10.1136/archdischild-2011-301398. Epub 2012 Aug 4.

Abstract

Purpose: The Cystic Fibrosis Trust in 2007 published a recommended target of 75-150 nmol/L for 25-hydroxyvitamin D (25-OHD). In 2008 we found that only 10% of pancreatic insufficient (PI) children met this target. An increase in supplementation was implemented and a repeat audit performed in 2010.

Methods: PI children ≥1 year under sole-care in our regional centre were included. Vitamin D3 supplementation increased by >450% to either 3800 IU/day liquid or 800 IU daily plus 20,000 IU weekly tablets. In 2010 pancreatic sufficient (PS) children were also audited separately.

Results: The median 25-OHD level increased from 51.5 nmol/L in 2008 (n=78, 10% >75 nmol/L) to 72 nmol/L in 2010 (n=72, 51% >75 nmol/L), p<0.0001. In PS children (n=15 in 2010) 87% had 25-OHD levels <75 nmol/L.

Conclusions: A substantial increase in supplementation led to a significant increase in 25-OHD levels but around half still failed to reach the recommended target.

MeSH terms

  • Adolescent
  • Calcifediol / blood*
  • Calcifediol / therapeutic use
  • Child
  • Child, Preschool
  • Cystic Fibrosis / blood*
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / physiopathology
  • Dietary Supplements
  • Exocrine Pancreatic Insufficiency / drug therapy*
  • Exocrine Pancreatic Insufficiency / etiology
  • Humans
  • Infant
  • Medical Audit
  • Vitamin D Deficiency / drug therapy*
  • Vitamin D Deficiency / etiology

Substances

  • Calcifediol